ArticleReproductive sciences (Thousand Oaks, Calif.)2025
Effects of Selective Serotonin Reuptake Inhibitors and Ondansetron on Urinary Tract Infections in Pregnancy.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Scoping Review of 5-HTPharmacoepidemiology and drug safety · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Urinary tract infections (UTIs) are prevalent during pregnancy and pose risks of adverse outcomes. Recent research suggests that urethral serotonin signaling may protect against ascending uropathogens. With the common use of Selective Serotonin Reuptake Inhibitors (SSRIs) and ondansetron, a serotonin receptor antagonist, during pregnancy, it is essential to explore their interactions with serotonin mechanisms to improve maternal health care. This study examines the relationship between SSRIs and ondansetron use in pregnancy and the incidence of UTIs and other negative outcomes. A retrospective analysis of data from 7,023 pregnant women in the PeriBank database (IRB ID: 2023-0263), from February 2020 to April 2023, revealed that 1,019 received ondansetron and 316 were on SSRIs, including fluoxetine, sertraline, escitalopram, and citalopram. An experimental component involving pregnant mice treated with ondansetron or saline before E. coli infection further assessed UTI severity. Findings indicated that pregnant women using ondansetron had significantly increased odds of developing UTIs, while no significant association was noted for those on SSRIs. Additionally, pregnant mice administered ondansetron exhibited more severe bladder infections compared to those given saline. These results suggest SSRIs are not linked to an increased UTI risk or adverse outcomes, whereas ondansetron is associated with higher UTI risk and pre-term birth. Thus, careful use of ondansetron during pregnancy is recommended to avoid potential risks to maternal and fetal health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.